Search

Your search keyword '"Yagisawa, Masataka"' showing total 45 results
Start Over Author "Yagisawa, Masataka"
45 results on '"Yagisawa, Masataka"'

1. Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

Author

Yagisawa, Masataka, Taniguchi, Hiroya, Satoh, Taroh, Kadowaki, Shigenori, Sunakawa, Yu, Nishina, Tomohiro, Komatsu, Yoshito, Esaki, Taito, Sakai, Daisuke, Doi, Ayako, Kajiwara, Takeshi, Ono, Hiromi, Asano, Masatoshi, Hirano, Nami, Odegaard, Justin, Fujii, Satoshi, Nomura, Shogo, Bando, Hideaki, Sato, Akihiro, Yoshino, Takayuki, and Nakamura, Yoshiaki

Published
2024
Full Text
View/download PDF

2. Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Author

Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, and Komatsu, Yoshito

Published
2022
Full Text
View/download PDF

3. Feasibility of edoxaban for asymptomatic cancer-associated thrombosis in Japanese patients with gastrointestinal cancer: ExCAVE study

Author

Nakamura, Michio, Ishiguro, Atsushi, Dazai, Masayoshi, Kawamoto, Yasuyuki, Yuki, Satoshi, Sogabe, Susumu, Hosokawa, Ayumu, Sawada, Kentaro, Muto, Osamu, Izawa, Naoki, Nakashima, Koji, Horie, Yoshiki, Yagisawa, Masataka, Kajiura, Shinya, Ando, Takayuki, Mitsuhashi, Yosuke, Sunakawa, Yu, Kikuchi, Yasuka, and Komatsu, Yoshito

Published
2022
Full Text
View/download PDF

5. Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival (OSERO study).

Author

Chida, Akihiko, primary, Kawakami, Takeshi, additional, Hamano, Tetsutaro, additional, Masuishi, Toshiki, additional, Mitani, Seiichiro, additional, Yasui, Hisateru, additional, Ishiguro, Atsushi, additional, Ando, Takayuki, additional, Sawada, Kentaro, additional, Harada, Kazuaki, additional, Takahashi, Naoki, additional, Boku, Shogen, additional, Kashiwada, Tomomi, additional, Esaki, Taito, additional, Yagisawa, Masataka, additional, Sugiyama, Keiji, additional, Yamamoto, Kouji, additional, Yuki, Satoshi, additional, Yamazaki, Kentaro, additional, and Oki, Eiji, additional

Published
2024
Full Text
View/download PDF

7. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma : A Multicenter, Retrospective Cohort Study (HGCSG2101)

Author

Harada, Kazuaki, Yamamura, Takahiro, Muto, Osamu, Nakamura, Michio, Sogabe, Susumu, Sawada, Kentaro, Nakano, Shintaro, Yagisawa, Masataka, Muranaka, Tetsuhito, Dazai, Masayoshi, Tateyama, Miki, Kobayashi, Yoshimitsu, Kato, Sosuke, Hatanaka, Kazuteru, Kawamoto, Yasuyuki, Yuki, Satoshi, Sakata, Yuh, Sakamoto, Naoya, 1000060333598, Komatsu, Yoshito, Harada, Kazuaki, Yamamura, Takahiro, Muto, Osamu, Nakamura, Michio, Sogabe, Susumu, Sawada, Kentaro, Nakano, Shintaro, Yagisawa, Masataka, Muranaka, Tetsuhito, Dazai, Masayoshi, Tateyama, Miki, Kobayashi, Yoshimitsu, Kato, Sosuke, Hatanaka, Kazuteru, Kawamoto, Yasuyuki, Yuki, Satoshi, Sakata, Yuh, Sakamoto, Naoya, 1000060333598, and Komatsu, Yoshito

Abstract

The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade >= 3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade >= 3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naive-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy.

Published
2023

8. Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)

Author

Harada, Kazuaki, primary, Yamamura, Takahiro, additional, Muto, Osamu, additional, Nakamura, Michio, additional, Sogabe, Susumu, additional, Sawada, Kentaro, additional, Nakano, Shintaro, additional, Yagisawa, Masataka, additional, Muranaka, Tetsuhito, additional, Dazai, Masayoshi, additional, Tateyama, Miki, additional, Kobayashi, Yoshimitsu, additional, Kato, Sosuke, additional, Hatanaka, Kazuteru, additional, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Sakata, Yuh, additional, Sakamoto, Naoya, additional, and Komatsu, Yoshito, additional

Published
2023
Full Text
View/download PDF

9. O15-2 HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy

Author

Yokoyama, Tatsuya, primary, Ito, Ken, additional, Yuki, Satoshi, additional, Nakatsumi, Hiroshi, additional, Ando, Takayuki, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Iwanaga, Ichiro, additional, Hatanaka, Kazuteru, additional, Sato, Atsushi, additional, Matsumoto, Ryusuke, additional, Shindo, Yoshiaki, additional, Tateyama, Miki, additional, Muranaka, Tetsuhito, additional, Katagiri, Masaki, additional, Yokota, Isao, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2022
Full Text
View/download PDF

10. MO2-2 HGCSG2101: A real-world analysis of nanoliposomal irinotecan plus 5-FU/LV in pancreatic ductal adenocarcinoma

Author

Dazai, Masayoshi, primary, Harada, Kazuaki, additional, Yamamura, Takahiro, additional, Muto, Osamu, additional, Nakamura, Michio, additional, Sogabe, Susumu, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Muranaka, Tetsuhito, additional, Nakano, Shintaro, additional, Tateyama, Miki, additional, Ito, Ken, additional, Saito, Rika, additional, Kobayashi, Yoshimitsu, additional, Kato, Sosuke, additional, Miyagishima, Takuto, additional, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2022
Full Text
View/download PDF

11. Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer

Author

Ken, Ito, Satoshi, Yuki, Hiroshi, Nakatsumi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito, Ken, Ito, Satoshi, Yuki, Hiroshi, Nakatsumi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, and Komatsu, Yoshito

Abstract

Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. Methods This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. Results From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 mu g/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 mu g/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). Conclusion There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia.

Published
2022

12. HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer.

Author

Ito, Ken, primary, Yuki, Satoshi, additional, Nakatsumi, Hiroshi, additional, Ando, Takayuki, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Iwanaga, Ichiro, additional, Hatanaka, Kazuteru, additional, Sato, Atsushi, additional, Matsumoto, Ryusuke, additional, Shindo, Yoshiaki, additional, Tateyama, Miki, additional, Muranaka, Tetsuhito, additional, Katagiri, Masaki, additional, Yokota, Isao, additional, Sakata, Yuh, additional, Sakamoto, Naoya, additional, and Komatsu, Yoshito, additional

Published
2022
Full Text
View/download PDF

13. The Feasibility of Edoxaban for Asymptomatic Cancer-associated Thrombosis in Japanese Gastrointestinal Cancer Patients (ExCAVE study)

Author

Nakamura, Michio, primary, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Sogabe, Susumu, additional, Hosokawa, Ayumu, additional, Sawada, Kentaro, additional, Muto, Osamu, additional, Izawa, Naoki, additional, Nakashima, Koji, additional, Horie, Yoshiki, additional, Yagisawa, Masataka, additional, Kajiura, Shinya, additional, Ando, Takayuki, additional, Mitsuhashi, Yosuke, additional, Sunakawa, Yu, additional, Kikuchi, Yasuka, additional, and Komatsu, Yoshito, additional

Published
2021
Full Text
View/download PDF

14. HGCSG1902 Multicenter, Prospective, Observational Study of Chemotherapy-induced Dysgeusia in Gastrointestinal Cancer

Author

Ito, Ken, primary, Yuki, Satoshi, additional, Nakatsumi, Hiroshi, additional, Kawamoto, Yasuyuki, additional, Harada, Kazuaki, additional, Nakano, Shintaro, additional, Saito, Rika, additional, Ando, Takayuki, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Iwanaga, Ichiro, additional, Hatanaka, Kazuteru, additional, Sato, Atsushi, additional, Matsumoto, Ryusuke, additional, Shindo, Yoshiaki, additional, Tateyama, Miki, additional, Muranaka, Tetsuhito, additional, Katagiri, Masaki, additional, Yokota, Isao, additional, Sakata, Yuh, additional, Sakamoto, Naoya, additional, and Komatsu, Yoshito, additional

Published
2021
Full Text
View/download PDF

15. The efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602).

Author

Nakamura, Michio, primary, Muranaka, Tetsuhito, additional, Yagisawa, Masataka, additional, Kawamoto, Yasuyuki, additional, Satoshi, Yuki, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Kobayashi, Yoshimitsu, additional, Sogabe, Susumu, additional, Harada, Kazuaki, additional, Sawada, Kentaro, additional, Miyagishima, Takuto, additional, Tsuji, Yasushi, additional, Kikuchi, Yasuka, additional, and Komatsu, Yoshito, additional

Published
2021
Full Text
View/download PDF

18. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

Author

Kawamoto, Yasuyuki, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Hayashi, Hideyuki, Yuki, Satoshi, Sawada, Kentaro, Yagisawa, Masataka, Nakano, Shintaro, Sakamoto, Naoya, Komatsu, Yoshito, Kawamoto, Yasuyuki, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Hayashi, Hideyuki, Yuki, Satoshi, Sawada, Kentaro, Yagisawa, Masataka, Nakano, Shintaro, Sakamoto, Naoya, and Komatsu, Yoshito

Abstract

Lessons Learned Because S-1 is orally administered, OX-IRIS does not necessitate the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS was determined to be level -1 (oxaliplatin, 65 mg/m(2); irinotecan, 100 mg/m(2); S-1, 80 mg/m(2)), which has manageable safety and promising anticancer activities. Background OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be beneficial because S-1 is administered orally and continuous infusion of 5-fluorouracil (5-FU) is not needed. Methods Patients who had not received prior therapy for unresectable PDAC were enrolled. Adenocarcinoma or adenosquamous histology was required. Oxaliplatin and irinotecan were administered on days 1 and 15; S-1 was administered orally twice a day on days 1-14, followed by 14 days of rest (one cycle). Primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results In level 0 (oxaliplatin, 85 mg/m(2); irinotecan, 100 mg/m(2); S-1, 80 mg/m(2)), two of five patients experienced DLT. In level -1 (oxaliplatin, 65 mg/m(2); irinotecan, 100 mg/m(2); S-1, 80 mg/m(2)), DLT could not be evaluated in two of eight patients because one cycle was not completed; one of the remaining six patients experienced DLT. Anemia, thrombocytopenia, fatigue, nausea, anorexia, diarrhea, and peripheral sensory neuropathy were seen frequently in levels 0 and -1. ORR was 30% in levels 0 and -1. Median progression-free survival and median overall survival were 4.1 months (95% confidence interval [CI], 0.0-8.9 months) and 13.7 months (95% CI, 4.8-22.6 months), respectively. Conclusion MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level -1.

Published
2021

19. A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403)

Author

Kawamoto, Yasuyuki, primary, Nakatsumi, Hiroshi, additional, Harada, Kazuaki, additional, Muranaka, Tetsuhito, additional, Ishiguro, Atsushi, additional, Kobayashi, Yoshimitsu, additional, Hayashi, Hideyuki, additional, Yuki, Satoshi, additional, Sawada, Kentaro, additional, Yagisawa, Masataka, additional, Nakano, Shintaro, additional, Sakamoto, Naoya, additional, and Komatsu, Yoshito, additional

Published
2021
Full Text
View/download PDF

20. A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602).

Author

Nakamura, Michio, primary, Muranaka, Tetsuhito, additional, Yagisawa, Masataka, additional, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Ishiguro, Atsushi, additional, Dazai, Masayoshi, additional, Kobayashi, Yoshimitsu, additional, Sogabe, Susumu, additional, Harada, Kazuaki, additional, Sawada, Kentaro, additional, Miyagishima, Takuto, additional, Tsuji, Yasushi, additional, Kikuchi, Yasuka, additional, and Komatsu, Yoshito, additional

Published
2021
Full Text
View/download PDF

21. A basket trial of trastuzumab deruxtecan, a HER2-targeted antibody-drug conjugate, for HER2-amplified solid tumors identified by circulating tumor DNA analysis (HERALD trial).

Author

Yagisawa, Masataka, primary, Nakamura, Yoshiaki, additional, Yoshino, Takayuki, additional, Komatsu, Yoshito, additional, Kadowaki, Shigenori, additional, Muro, Kei, additional, Sunakawa, Yu, additional, Satoh, Taroh, additional, Nishina, Tomohiro, additional, Esaki, Taito, additional, Fujii, Satoshi, additional, Ono, Hiromi, additional, Tomita, Daiki, additional, Fujishiro, Noriko, additional, Hirano, Nami, additional, Fuse, Nozomu, additional, Sato, Akihiro, additional, Ogawa, Gakuto, additional, Nomura, Shogo, additional, and Taniguchi, Hiroya, additional

Published
2020
Full Text
View/download PDF

22. Molecular landscape and prognostic value of HER2 low-expression on metastatic colorectal cancer.

Author

Yagisawa, Masataka, primary, Sawada, Kentaro, additional, Nakamura, Yoshiaki, additional, Ishii, Takahiro, additional, Kubota, Yohei, additional, Nakajima, Hiromichi, additional, Jogo, Tomoko, additional, Sasaki, Akinori, additional, Mishima, Saori, additional, Kotani, Daisuke, additional, Kawazoe, Akihito, additional, Kuboki, Yasutoshi, additional, Shitara, Kohei, additional, Kojima, Takashi, additional, Doi, Toshihiko, additional, Ohtsu, Atsushi, additional, Fujii, Satoshi, additional, Yoshino, Takayuki, additional, and Taniguchi, Hiroya, additional

Published
2020
Full Text
View/download PDF

23. Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study)

Author

Aonuma, Ayane Oba, primary, Nakamura, Michio, additional, Sakamaki, Kentaro, additional, Murai, Taichi, additional, Matsuda, Chika, additional, Itaya, Kazufumi, additional, Sone, Takayuki, additional, Yagisawa, Masataka, additional, Koike, Yuta, additional, Endo, Ayana, additional, Tsukuda, Yoko, additional, Ono, Yuji, additional, Nagasaka, Atsushi, additional, Nishikawa, Shuji, additional, Yamanaka, Takeharu, additional, and Sakamoto, Naoya, additional

Published
2019
Full Text
View/download PDF

24. A MULTICENTER PROSPECTIVE STUDY ON THE EFFICACY AND SAFETY OF DENOSUMAB IN GASTROINTESTINAL CANCER PATIENTS RECEIVING SHORT-TERM PERIODIC STEROID PREMEDICATION FOR PREVENTION OF CINV. (ESPRESSO-02/HGCSG1602)

Author

Nakamura, Michio, primary, Muranaka, Tetsuhito, primary, Yagisawa, Masataka, primary, Kawamoto, Yasuyki, primary, Yuki, Satoshi, primary, Ishiguro, Atsushi, primary, Dazai, Masayoshi, primary, Sogabe, Susumu, primary, Harada, Kazuaki, primary, Kobayashi, Yoshimitsu, primary, Miyagishima, Takuto, primary, Tsuji, Yasushi, primary, and Komatsu, Yoshito, primary

Published
2019
Full Text
View/download PDF

25. Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy : a single-institutional retrospective cohort analysis (Sapporo CAT study)

Author

Aonuma, Ayane Oba, Nakamura, Michio, Sakamaki, Kentaro, Murai, Taichi, Matsuda, Chika, Itaya, Kazufumi, Sone, Takayuki, Yagisawa, Masataka, Koike, Yuta, Endo, Ayana, Tsukuda, Yoko, Ono, Yuji, Nagasaka, Atsushi, Nishikawa, Shuji, 1000000325466, Yamanaka, Takeharu, 1000010334418, Sakamoto, Naoya, Aonuma, Ayane Oba, Nakamura, Michio, Sakamaki, Kentaro, Murai, Taichi, Matsuda, Chika, Itaya, Kazufumi, Sone, Takayuki, Yagisawa, Masataka, Koike, Yuta, Endo, Ayana, Tsukuda, Yoko, Ono, Yuji, Nagasaka, Atsushi, Nishikawa, Shuji, 1000000325466, Yamanaka, Takeharu, 1000010334418, and Sakamoto, Naoya

Abstract

Objective Few data regarding the incidence of cancer-associated thromboembolism (TE) are available for Asian populations. We investigated the incidence of TE (TEi) and its risk factors among gastric and colorectal cancer (GCC) patients received chemotherapy in a daily practice setting. Design A retrospective cohort study. Setting A single-institutional study that used data from Sapporo City General Hospital, Japan, on patients treated between January 2008 and May 2015. Participants Five hundred Japanese GCC patients who started chemotherapy from January 2008 to May 2015. Primary and secondary outcome measures TE was diagnosed by reviewing all the reports of contrast-enhanced CT performed during the follow-up period. All types of thrombosis detected by CT or additional imaging tests, such as venous TE, arterial TE and cerebral infarction, were defined as TE. Medical records of all identified patients were reviewed and potential risk factors for TE, including clinicopathological backgrounds, were collected. We defined the following patients as 'active cancer'; patients with unresectable advanced GCC, cancer recurrence during or after completing adjuvant chemotherapy and/or presence of other malignant tumours. Results Of the 500 patients, 70 patients (14.0%) developed TE during the follow-up period. TEi was 9.2% and 17.3% in GCC patients, 18.1% and 3.5% in active and non-active cancer patients, and 24.0% and 12.9% in multiple and single primary, respectively. Multivariate logistic regression analysis showed that colorectal cancer (CRC) (OR 2.371; 95% CI 1.328 to 4.233), active cancer (OR 7.593; 95%CI 2.950 to 19.543) and multiple primary (OR 2.527; 95%CI 1.189 to 5.370) were independently associated with TEi. Conclusion TEi was 14.0% among Japanese GCC patients received chemotherapy, and was significantly higher among patients with CRC, active cancer and multiple primary than among those with gastric cancer, non-active cancer and single primary, respectively. Trial reg

Published
2019

27. Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.

Author

Nakano, Shintaro, primary, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Yagisawa, Masataka, additional, Sawada, Kentaro, additional, Muranaka, Tetsuhito, additional, Nakatsumi, Hiroshi, additional, Saiki, Takuro, additional, Ishiguro, Atsushi, additional, Harada, Kazuaki, additional, Kobayashi, Yoshimitsu, additional, Iwanaga, Ichiro, additional, Hatanaka, Kazuteru, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2019
Full Text
View/download PDF

29. A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of tumor location.

Author

Ogawa, Kohei, primary, Yuki, Satoshi, additional, Kawamoto, Yasuyuki, additional, Yagisawa, Masataka, additional, Harada, Kazuaki, additional, Okuda, Hiroyuki, additional, Furukawa, Kouichi, additional, Honda, Takuya, additional, Dazai, Masayoshi, additional, Kato, Takashi, additional, Sasaki, Takahide, additional, Shindo, Yoshiaki, additional, Ota, Sakae, additional, Sato, Atsushi, additional, Ueda, Akira, additional, Kato, Sosuke, additional, Fukunaga, Akira, additional, Nagai, Hikari, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2018
Full Text
View/download PDF

30. HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab

Author

Sasaki, Takahide, primary, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Meguro, Takashi, additional, Hatanaka, Kazuteru, additional, Uebayashi, Minoru, additional, Iwanaga, Ichiro, additional, Nakamura, Michio, additional, Eto, Kazunori, additional, Okuda, Hiroyuki, additional, Abe, Masakazu, additional, Oba, Ayane, additional, Abe, Nobuhiko, additional, Sato, Atsushi, additional, Nakatsumi, Hiroshi, additional, Harada, Kazuaki, additional, Muranaka, Tetsuhito, additional, Yagisawa, Masataka, additional, Oba, Koji, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2017
Full Text
View/download PDF

33. A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01)

Author

Nakamura, Michio, Ishiguro, Atsushi, Muranaka, Tetsuhito, Fukushima, Hiraku, Yuki, Satoshi, Ono, Kota, Murai, Taichi, Matsuda, Chika, Oba, Ayane, Itaya, Kazufumi, Sone, Takayuki, Yagisawa, Masataka, Koike, Yuta, Endo, Ayana, Tsukuda, Yoko, Ono, Yuji, Kudo, Takahiko, Nagasaka, Atsushi, Nishikawa, Shuji, Komatsu, Yoshito, Nakamura, Michio, Ishiguro, Atsushi, Muranaka, Tetsuhito, Fukushima, Hiraku, Yuki, Satoshi, Ono, Kota, Murai, Taichi, Matsuda, Chika, Oba, Ayane, Itaya, Kazufumi, Sone, Takayuki, Yagisawa, Masataka, Koike, Yuta, Endo, Ayana, Tsukuda, Yoko, Ono, Yuji, Kudo, Takahiko, Nagasaka, Atsushi, Nishikawa, Shuji, and Komatsu, Yoshito

Abstract

Background. A multicenter prospective observational study evaluated the effect of gastrointestinal cancer chemotherapy with short‐term periodic steroid premedication on bone metabolism. Patients and Methods. Seventy‐four patients undergoing chemotherapy for gastrointestinal cancer were studied. The primary endpoints were changes in bone mineral densities (BMDs) and metabolic bone turnover 16 weeks after initiation of chemotherapy. BMDs, measured by dual‐energy x‐ray absorptiometry, and serum cross‐linked N‐telopeptides of type I collagen (sNTX), and bone alkaline phosphatase (sBAP) were assessed for evaluation of bone resorption and formation, respectively. Results. In 74.3% (55/74) of the patients, BMDs were significantly reduced at 16 weeks relative to baseline. The percent changes of BMD were -1.89% (95% confidence interval [CI], -2.67% to -1.11%: p < .0001) in the lumbar spine, -2.24% (95% CI, -3.59% to -0.89%: p = .002) in the total hip, and -2.05% (95% CI, -3.11% to -0.99%: p < .0001) in the femoral neck. Although there was no significant difference in sNTX levels during 16 weeks (p = .136), there was a significant increase in sBAP levels (p = .010). Decreased BMD was significantly linked to number of chemotherapy cycles (p = .02). There were no significant correlations between changes in BMDs and the primary site of malignancy, chemotherapy regimens, total cumulative steroid dose, steroid dose intensity, and additive steroid usage. Conclusion. Gastrointestinal cancer chemotherapy with periodic glucocorticoid premedication was associated with reduced BMD and increased sBAP levels, which were linked to number of chemotherapy cycles but independent of primary site, chemotherapy regimen, duration, and additive steroid usage.

Published
2017

34. A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01)

Author

Nakamura, Michio, primary, Ishiguro, Atsushi, additional, Muranaka, Tetsuhito, additional, Fukushima, Hiraku, additional, Yuki, Satoshi, additional, Ono, Kota, additional, Murai, Taichi, additional, Matsuda, Chika, additional, Oba, Ayane, additional, Itaya, Kazufumi, additional, Sone, Takayuki, additional, Yagisawa, Masataka, additional, Koike, Yuta, additional, Endo, Ayana, additional, Tsukuda, Yoko, additional, Ono, Yuji, additional, Kudo, Takahiko, additional, Nagasaka, Atsushi, additional, Nishikawa, Shuji, additional, and Komatsu, Yoshito, additional

Published
2017
Full Text
View/download PDF

35. A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602.

Author

Nakamura, Michio, primary, Yagisawa, Masataka, additional, Sawada, Kentaro, additional, Muranaka, Tetsuhito, additional, Nakatsumi, Hiroshi, additional, Kawamoto, Yasuyuki, additional, Yuki, Satoshi, additional, Dazai, Masayoshi, additional, Ishiguro, Atsushi, additional, Kobayashi, Yoshimitsu, additional, Sogabe, Susumu, additional, Miyagishima, Takuto, additional, Iwanaga, Ichiro, additional, Tateyama, Miki, additional, Hatanaka, Kazuteru, additional, Ono, Kota, additional, Sakata, Yuh, additional, and Komatsu, Yoshito, additional

Published
2017
Full Text
View/download PDF

37. Feasibility Study of Bolus 5-Fluorouracil+L-Leucovorin as Salvage Line Chemotherapy for Oral Fluorouracil-Resistant Unresectable Gastric Cancer: Hokkaido Gastrointestinal Cancer Study Group Study HGCSG1502

Author

Muranaka, Tetsuhito, primary, Komatsu, Yoshito, additional, Yagisawa, Masataka, additional, Sawada, Kentaro, additional, Harada, Kazuaki, additional, Kawamoto, Yasuyuki, additional, Nakatsumi, Hiroshi, additional, Yuki, Satoshi, additional, Ono, Kota, additional, Kawahata, Shuhei, additional, Kobayashi, Yoshimitsu, additional, Sogabe, Susumu, additional, Miyagishima, Takuto, additional, Hatanaka, Kazuteru, additional, Sasaki, Takahide, additional, Dazai, Masayoshi, additional, Iwanaga, Ichiro, additional, Ishiguro, Atsushi, additional, Nakamura, Michio, additional, Sakamoto, Naoya, additional, and Sakata, Yuh, additional

Published
2017
Full Text
View/download PDF

40. P-086 - HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab

Author

Sasaki, Takahide, Kawamoto, Yasuyuki, Yuki, Satoshi, Meguro, Takashi, Hatanaka, Kazuteru, Uebayashi, Minoru, Iwanaga, Ichiro, Nakamura, Michio, Eto, Kazunori, Okuda, Hiroyuki, Abe, Masakazu, Oba, Ayane, Abe, Nobuhiko, Sato, Atsushi, Nakatsumi, Hiroshi, Harada, Kazuaki, Muranaka, Tetsuhito, Yagisawa, Masataka, Oba, Koji, Sakata, Yuh, and Komatsu, Yoshito

Published
2017
Full Text
View/download PDF

41. Weekly nanoparticle albumin-bound paclitaxel(nab-PTX) as second-or later-line treatment for unresectable or recurrent gastric cancer in practice.

Author

Yagisawa, Masataka, primary, Sogabe, Susumu, additional, Iwanaga, Ichiro, additional, Oshino, Tomohiro, additional, Yamamura, Takahiro, additional, Hirata, Hajime, additional, Nakajima, Masahito, additional, Suzuki, Kazuharu, additional, Shimono, Joji, additional, Takasaka, Takuma, additional, Takahashi, Kazuhiro, additional, Kobayashi, Yoshimitsu, additional, Kudo, Taiki, additional, Okada, Kohei, additional, Dazai, Masayoshi, additional, Oda, Hisashi, additional, and Miyagishima, Takuto, additional

Published
2015
Full Text
View/download PDF

43. Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806).

Author

Taniguchi, Hiroya, Yagisawa, Masataka, Satoh, Taroh, Kadowaki, Shigenori, Sunakawa, Yu, Nishina, Tomohiro, Komatsu, Yoshito, Esaki, Taito, Sakai, Daisuke, Doi, Ayako, Kajiwara, Takeshi, Ono, Hiromi, Asano, Masatoshi, Hirano, Nami, Odegaard, Justin Iver, Fujii, Satoshi, Nomura, Shogo, Sato, Akihiro, Yoshino, Takayuki, and Nakamura, Yoshiaki

Published
2023
Full Text
View/download PDF

44. Multi-organ disseminated mucosa-associated lymphoid tissue lymphoma.

Author

Naruse H, Tanaka I, Yagisawa M, Kudo T, Horimoto M, Yamamoto K, Hatanaka K, Yamamoto Y, and Shimoyama N

Subjects
Endoscopic Ultrasound-Guided Fine Needle Aspiration, Humans, Male, Middle Aged, Lymphoma, B-Cell, Marginal Zone pathology
Abstract

A 61-year-old man was admitted to our hospital with extreme weight loss. Abdominal ultrasonography revealed an 8-cm tumor of the pancreatic head. Further investigation revealed orbital, pulmonary, pancreatic, colonic, and bone marrow lesions. A histopathological examination of the pancreatic tumor specimen obtained using endoscopic ultrasound-guided fine-needle aspiration revealed mucosa-associated lymphoid tissue (MALT) lymphoma. Monoclonal rearrangement of immunoglobulin heavy chain was found in the pulmonary, pancreatic, colonic, and bone marrow lesions. We diagnosed multi-organ disseminated MALT lymphoma, with the largest lesion located in the pancreatic head. Chemo-radiation therapy resulted in complete remission.

Published
2016
Full Text
View/download PDF

45. [Clinical impact of addition of bevacizumab to the first-line chemotherapy regimen in the treatment of patients with metastatic colorectal cancer].

Author

Sogabe S, Tateno T, Yagisawa M, Ishikawa M, Sawada K, Muranaka T, Umemura M, Kato R, Takasaka T, Takahashi K, Dazai M, Iwanaga I, Oda H, and Miyagishima T

Subjects
Adult, Aged, Aged, 80 and over, Bevacizumab, Colorectal Neoplasms pathology, Disease Progression, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Retrospective Studies, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy
Abstract

Background: Combination regimens containing bevacizumab(BV)are regarded as one of the standard first-line chemotherapy (1stCTx) regimens in the treatment of metastatic colorectal cancer (mCRC). However, some patients cannot be treated with BV because of the short interval from the palliative operation or other reasons. We present a study of some patients who were treated with add-on BV in the middle of the 1stCTx before disease progression(referred to as "midway BV" regimen hereafter), and here, we report the efficacy of the midway BV regimen as observed in our patients., Results: We retrospectively analyzed the data of 74 mCRC patients, who were undergoing 1stCTx treatment at our hospital from January 2010 to September 2012. We divided the patients into 3 groups, depending on when BV was introduced in their regimen: 40, 25, and 9 patients were respectively included in the "no-BV" group (patients who were treated without BV in the 1stCTx), BV group(patients treated with BV from the 1st cycle in the 1stCTx), and the midway-BV group (patients who were initially treated without BV and then received add-on BV). The response rates of patients in the no-BV, BV, and midway-BV groups were 27.5%, 44.0%, and 55.6%, respectively. The median progression-free survival (PFS) and median survival time of patients in the no-BV, BV, and midway-BV groups were, respectively, 9.7 months, 9.3 months, and 12.8 months, and 20.3 months, 22.2 months, and N. R., Conclusion: Although few cases were analyzed and there might be many confounding factors, our study suggests that midway BV is potentially useful for patients with metastatic colorectal cancer who are not initially treated with BV in the first cycle of the 1stCTx regimen.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results